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ARTICLE
A cross-reactive human IgA monoclonal antibody
blocks SARS-CoV-2 spike-ACE2 interaction
Monir Ejemel1,5, Qi Li1,5, Shurong Hou 2,5, Zachary A. Schiller 1,5, Julia A. Tree3, Aaron Wallace1,
Alla Amcheslavsky1, Nese Kurt Yilmaz2, Karen R. Buttigieg3, Michael J. Elmore 3, Kerry Godwin3,
Naomi Coombes3, Jacqueline R. Toomey1, Ryan Schneider1, Anudeep S. Ramchetty1, Brianna J. Close 4,
Da-Yuan Chen4, Hasahn L. Conway 4, Mohsan Saeed4, Chandrashekar Ganesa1, Miles W. Carroll3,
Lisa A. Cavacini 1✉, Mark S. Klempner1✉, Celia A. Schiffer 2✉ & Yang Wang 1✉
COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development
of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine
to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In
this study, we discover and characterize a cross-reactive human IgA monoclonal antibody,
MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competi-
tively blocks ACE2 receptor binding, by overlapping the ACE2 structural binding epitope.
Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in 293
cells expressing ACE2. When converted to secretory IgA, MAb326 also neutralizes authentic
SARS-CoV-2 virus while the IgG isotype shows no neutralization. Our results suggest that
SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity
against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a
potentially critical feature of an effective vaccine.
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In December 2019, a novel coronavirus (SARS-CoV-2) wasidentified as the cause of an outbreak of acute respiratoryinfections. The coronavirus disease 2019 (COVID-19) ranges
from mild to severe acute respiratory infection, with a fatality rate
estimated to range from 2 to 3%1–4. Within 3 months of the first
report cases, COVID-19 rapidly disseminated through the human
population and had become a global pandemic by March 2020.
Phylogenic analysis has classified SARS-CoV-2 within the sar-
becoviruses subgenus, the β lineage that also contains SARS-CoV,
sharing ~79.6% sequence identity4.
Interventions for the prevention or treatment of COVID-19 are
crucial for the ongoing outbreak. Pre- or post-exposure immu-
notherapies with neutralizing antibodies, would be of great use by
providing immediate mucosal immunity against SARS-CoV-2.
Although concerns, as occurred with SARS-CoV5,6, that vaccines
may cause disease enhancement still need to be addressed. The
feasibility of human monoclonal antibodies (MAbs) as immu-
noprophylaxis or therapy against coronaviruses including SARS-
CoV7–10 and MERS-CoV11 has been demonstrated. These anti-
coronavirus MAbs primarily target the viral spike (S) glycopro-
tein, a type I transmembrane glycoprotein that produces recog-
nizable crown-like spike structures on the virus surface. The
receptor-binding domain (RBD) of the S protein facilitates viral
entry into human cells through human angiotensin-converting
enzyme 2 (ACE2) receptor binding leveraging a similar
mechanism as SARS-CoV12–14.
Most current anti-SARS-CoV MAbs neutralize virus by bind-
ing to epitopes on the spike protein RBD of SARS-CoV15. We and
others have demonstrated that neutralizing MAbs that block
RBD-ACE2 binding could confer potent protection against
SARS-CoV as both prophylaxis and treatment in various animal
models7,9,10. Several anti-SARS-CoV MAbs have demonstrated
cross-neutralizing activities against the S protein of SARS-CoV-
216,17.
Antibody-dependent enhancement of viral infections are one
of the major hurdles in the development of effective vaccines.
This enhancement is likely facilitated by the Fc domain of IgG but
not for its isotype variant IgA18. The avidity of mucosal IgA, in
comparison with IgG, owing to the multimeric structure,
enhances the antibody binding with antigens. In addition, the
diverse, high level of glycosylation of IgA antibodies, further
protects the mucosal surface with non-specific interference. In
animal models, high titers of mucosal IgA in the lung is correlated
with reduced pathology upon viral challenge with SARS-CoV19.
How precisely which isotype may protect the mucosa from SARS-
CoV-2 infection remains an open question.
In the current study, we describe the discovery of a cross-
neutralizing human IgA monoclonal antibody, MAb362 IgA. This
IgA antibody binds to SARS-CoV-2 RBD with high affinity
competing at the ACE2 binding interface by blocking interactions
with the receptor. MAb362 IgA neutralizes both pseudotyped
SARS-CoV and SARS-CoV-2 in 293 cells expressing ACE2. The
secretory IgA form of MAb326 also neutralizes authentic SARS-
CoV-2 virus. Our results demonstrate that the IgA isotype may
play a critical role in SARS-CoV-2 neutralization.
Results
Selection of MAb binding to RBD of SARS-CoV-2 in ELISA.
We have previously developed and characterized a panel of
human MAbs that targets the RBD of the SARS-CoV S glyco-
protein, isolated from transgenic mice expressing human immu-
noglobulin genes9,10. These transgenic mice contains human
immunoglobulin genes and inactivated mouse heavy chain and
kappa light chain genes (Bristol-Myers Squibb). Transgenic mice
were immunized weekly with 10mg of SARS-CoV spike protein
and adjuvants for 6–8 weeks. Hybridomas were generated fol-
lowing a standard fusion protocol9. A panel of over 36 hybridomas
were isolated based on various neutralization activities against
SARS-CoV with lead antibodies showing protective potency in
mice and hamster models9,10. To explore the possibility that some
of the SARS-CoV-specific hybridoma may have cross-reactivity
against SARS-CoV-2, these hybridomas were recovered and
screened by ELISA against the SARS-CoV-2 spike protein.
MAb362 was identified with cross-binding activity against both
the RBD and S1 subunit of the SARS-CoV and SARS-CoV-2 spike
proteins (Supplementary Table 1).
While both IgG and IgA are expressed at the mucosa, IgA is more
effective on a molar basis and thus the natural choice for mucosal
passive immunization as we recently demonstrated in other mucosal
infectious disease20,21. To further characterize the functionality of
MAb362, variable sequences of MAb362 were cloned into
expression vectors as either IgG or monomeric IgA isotypes. Both
MAb362 IgG and IgA were assessed in ELISA-binding assays
against the RBD of the S1 subunit for SARS-CoV (S270–510) and
SARS-CoV-2 (S319–541) (Fig. 1a, b). MAb362 IgA showed better
binding activities, compared with its IgG counterpart against SARS-
CoV-2 S319–541 (Fig. 1b). Assessment of the binding kinetics was
consistent with the ELISA-binding trends. The binding affinity of
IgA with RBD of SARS-CoV-2 is significantly higher (0.3 nM) than
that of IgG (13 nM) due to a much slower dissociation rate as
an IgA (Koff= 1.13 × 10−3 ± 1.06 × 10−4) compared with an IgG
(Koff= 7.75 × 10−5 ± 5.46 × 10−5) (Fig. 1e, f). Of note, MAb362 IgA
and IgG showed similar binding affinity with SARS-CoV S270–510
(Fig. 1c, d).
To confirm binding results, the full ectodomain of spike was
expressed including residues 1−1208 of SARS-CoV-2 with
stabilizing proline mutations and a C-terminal T4 fibritin
trimerization motif as described recently22 (Supplementary Fig. 1).
MAb362 IgA still showed better binding activities with the
stabilized trimer form as compared with its IgG isotype in ELISA
(Fig. 1b) and affinity assays. The binding affinity of MAb362 IgA
with the ectodomain of SARS-CoV-2 is 0.17 nM as compared
with the 27 nM of IgG (Fig. 1g, h).
Structural modeling of MAb362 binding to RBD. To correlate
the epitope binding with functionality, MAb362 IgG and IgA
were tested in a receptor-blocking assay with Vero E6 cells. The
result suggested that both MAb362 IgG and IgA block SARS-
CoV-2 RBD binding to receptors in a concentration-dependent
manner starting at ~30 nM (Fig. 2a, Supplementary Fig. 2a).
Mutational scanning with a combination of alanine (to introduce
a loss of interaction), tryptophan (to introduce a steric challenge),
and lysine to introduce charge mutations were performed to
better delineate the binding surface (Fig. 2b). The results showed
that that key residues (Y449A, Y453A, F456A, A475W, Y489A,
and Q493W) were critical for the complex and presumably,
alterations in the packing caused marked loss of binding affinity
(Fig. 2b and Supplementary Fig. 2b). Among the mutant we
tested, A475W and Y489A also disrupted ACE2 binding (Sup-
plementary Fig. 3). Interestingly, introduction of lysine mutations
had little effect on binding, and some even showed enhanced
binding, presumably owing to an overall more favorable charged
interaction with the MAb362.
To better define the antibody-binding epitope, known co-
crystal and cryo-electron microscopy complexes from SARS-CoV
and MERS spike protein in complex with neutralizing antibodies
were evaluated for their potential to competitively block ACE2
binding, based on the structural interface of ACE2-SARS-CoV-2-
RBD (PDB ID-6VW1)23. The 80R-SARS-CoV-RBD complex
(PDB ID-2GHW)24, a crystal structure of SARS-CoV-RBD in
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complex with a neutralizing antibody, 80 R, was found most
closely to have these characteristics. When the sequence was
evaluated, we ascertained that the two antibodies, MAb362 and
80 R, had frameworks with 90% amino-acid sequence identity
(Supplementary Fig. 4). Thus, the crystal structure 2GHW
provided a suitable scaffold to generate a homology model of
MAb362. Protein–protein docking was performed using the
Schrodinger suite with tethers based on the mutational analysis.
The complex that satisfied the energetics and mutational data was
then further interrogated with a 300 ns fully solvated molecular
dynamics simulation in which the complex-structure remained
stable after equilibration. The final frame of the simulation is the
current model of the structure of the MAb362:SARS-CoV-2-RBD
complex (Fig. 2c).
The interface of the complex is predicted to form an extensive
interface (Fig. 2d and Supplementary Fig. 3) with the CDRs of
both the heavy and light chains forming interactions with SARS-
CoV-2-RBD. Interestingly, the mutational analysis in combina-
tion with this model indicates that the light chain’s contribution
to this complex may be more significant than the heavy chain
(Supplementary Fig. 3c). Complementing the receptor-blocking
assay and mutational analysis, our structural analysis further
confirms that the MAb362 epitope is directly competing for the
ACE2 binding epitope on SARS-CoV-2 spike protein.
MAb362 structural epitope. The model of the structure of the
MAb362:SARS-CoV-2-RBD complex permitted the superposition
of the ACE2:SARS-CoV-2-RBD (PDB: 6VWI23) (Fig. 3a).
MAb362 is predicted to overlaps with the ACE2 epitope on the
RBD. This interface of MAb362 (Fig. 2d) is very similar with the
ACE2 interface projected onto the SARS-CoV-2-RBD (Fig. 3b).
However, this predicted epitope of MAb362 is different from the
other recently reported MAb complexes to the SARS-CoV-2-RBD
(Fig. 3c and Supplementary Fig. 5), including: CR302217 (PDB:
6W41); S30916 (PDB: 6WPT); REGN10933 and REGN1098725;
(PDB: 6XDG); P2B-2F626 (PDB: 7BWJ); CB627 (PDB: 7C01) and
B3828 (PDB: 7BZ5). MAb362 is predicted to block ACE2-binding
interface through a unique epitope conserved between SARS-CoV
and SARS-CoV-2. This finding was consistent with the strong
activity of MAb362 of compromising RBD–receptor interaction.
As with the binding of ACE2, the predicted MAb362-binding
epitope can only be exposed if the RBD was in the open or up
conformation in the trimer (Fig. 3d). In the closed conformation,
this epitope would not be accessible to MAb362 without major
steric clashes. However, unlike CR3022 for instance, MAb362
could access the ACE2-binding epitope(s) if one or more of the
trimers is in this open conformation, potentially accounting for
the added neutralizing activity.
MAb362 IgA neutralizes SARS-CoV and SARS-CoV-2. To
evaluate the neutralization potency of cross-reactive MAb362, a
pseudovirus assay using lentiviral pseudovirions on 293T cells
expressing ACE2 receptor29 was performed. Both MAb362 IgG
and IgA showed potent neutralization activity against SARS-CoV
(Fig. 4a). MAb362 IgG weakly neutralized SARS-CoV-2 pseudo-
virus despite its activities to block receptor binding. Interestingly,
isotype switch to MAb362 IgA resulted in significantly enhanced
neutralization potency with an IC50 value of 1.26 µgml−1, com-
pared with its IgG subclass variant (IC50= 58.67 µgml−1)
(Fig. 4b). Monomeric MAb362 IgA was also co-expressed with J
chain to produce dimeric IgA (dIgA) and secretory component to
produce secretory IgA (sIgA) as described in Supplementary
Fig. 630. Both dIgA and sIgA were significantly more effective at
neutralizing SARS-CoV-2 pseudovirus with an IC50 of 30 ngml−1
and 10 ngml−1, respectively (Fig. 4b). Of note, all MAb362 IgG
and IgA isotype variants showed comparable neutralization
activity against SARS-CoV (Fig. 4a). Further, the most potent
form MAb362 sIgA was tested in authentic virus neutralization
assay against SARS-CoV-2. MAb362 sIgA neutralized SARS-CoV-
2 virus with an IC50 value of 9.54 µgml−1 (Fig. 4c). MAb362 IgG
failed to neutralize live virus at the highest tested concentration.
This is consistent with our prior study showing isotype switch to
IgA lead to improved antibody neutralization of HIV infection31.
Our data extend this observation to coronavirus, suggesting that
IgA may play an important role in SARS-CoV-2 neutralization.
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Fig. 1 Binding of MAb362 IgG and IgA to spikes of SARS-CoV and SARS-CoV-2. MAb362 IgG and IgA bind to purified SARS-CoV S1 (S1–590) and RBD
(S270–510) truncations a and SARS-CoV-2 S1 (S1–604), RBD (S319–541), and ectodomain trimer b. IgGs are red lines, IgAs are blue lines, and irrelevant IgGs are
black. Affinity measurements of MAb362 IgG c, e, g and IgA d, f, h against the RBD truncations of S glycoprotein of SARS-CoV and SARS-CoV-2 c–f, as
well as ectodomain trimer of SARS-CoV-2 g, h were conducted using bio-layer interferometry and demonstrate nano and sub-nanomolar affinities. Data
are plotted as the mean ± s.d. from n= 3 independent experiments a, b. Source data are provided as a Source Data file.
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Discussion
This study reports a unique cross-reactive epitope within the core
receptor-binding interface of the S protein of both SARS-CoV
and SARS-CoV-2. MAb362 IgA neutralizes the virus by com-
peting with S protein binding to ACE2 receptors. Interestingly,
our results show that despite the same blocking of spike inter-
action with ACE2, MAb362 IgG weakly neutralizes SARS-CoV-2,
whereas IgA as monomer, dimer, or secretory antibody has sig-
nificantly enhanced neutralization potency. Structural studies
demonstrated that IgA1 has a lengthy hinge region with a 13-a.a.
insertion and a relaxed “T” like structure as compared with the
more rigid “Y” like structure in IgG32,33. Thus, the increase
flexibility of IgA1 would likely afford a greater reach toward its
epitopes on the target and decrease steric hindrance. MAb362 IgA
binds when the spike protein (trimer) is in open form. The longer
IgA1 hinge may allow two Fabs to reach two RBDs of the trimer
at the same time without clashes, which may not be achieved by
the shorter hinge in IgG. Our results suggest that compared with
IgG, SARS-CoV-2-specific IgA antibody may play an important
independent role in providing protective mucosal immunity. A
similar finding has been observed for IgA antibodies to other
viruses such as influenza and HIV. When monoclonal antibodies
are expressed as IgG or IgA1 isotypes with identical variable
regions, antibody binding (affinity, breadth) as well as neu-
tralization are enhanced as IgA1 molecules34,35. Though serum
half-life of monomeric IgA is relatively short, at the mucosal
epithelial interface, IgA is typically present as secretory antibody.
Polymeric IgA (predominantly as a dimer) is produced by local
plasma cells and binds to the polymeric Ig receptor at the baso-
lateral surface, is transported through the epithelial cell for release
at the apical side as secretory IgA, which is the polymeric IgA
with addition of the secretory component contributed by the
polymeric Ig receptor. The secretory component protects the IgA
from harsh conditions prolonging half-life. In addition, the
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Fig. 2 Mutationally guided molecular modeling of MAb362 binding to RBD. a SARS-CoV-2 S1 was pre-incubated with MAb362 IgG (red circles) and IgA
(blue squares) ranging from ~2 to 2000 nM. Both MAb362 isotypes demonstrated concentration-dependent inhibition of SARS-CoV-2 RBD binding to
Vero E6 cells at concentrations >30 nM. Data are plotted as the mean ± s.d. from n= 3 independent experiments. bMutational scanning was performed to
better delineate the binding surface. Key residues were mutated and expressed as recombinant proteins. Identified critical residues (orange) were
experimental confirmed by shifts in EC50 values for MAb362 binding in ELISA relative to wild-type RBD (blue). EC50 values calculated from n= 3
independent experiments. c Surface representation of the predicted molecular model of MAb362 SARS-CoV-2 RBD complex; the light chain of MAb362
(light yellow), the heavy chain (green), and the SARS-CoV-2 RBD (violet). d The predicted binding interface on SARS-CoV-2 RBD with MAb362. The
residues identified by mutagenesis from b are labeled and colored according to influence degree; red represents strongest defects, orange for medium
defects and yellow for subtle defects. Source data are provided as a Source Data file a, b.
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carbohydrate moieties of sIgA molecules can bind to adhesion
molecules expressed by many pathogens and interfere initial
binding of virus to the target cells as the first line of defense. Thus,
mucosal passive immunization of secretory IgA directly to the
infection site could additionally be an effective approach of sys-
temic delivery of other IgG treatment to achieve immediate
protection. To date, innovative approaches are being explored for
sIgA production in mammalian and especially plant expression
systems for cost-effective production including ongoing work in
our laboratories36,37.
Other recent structure studies have characterized antibodies
targeting the RBD domain distal from the receptor-binding
core interface of SARS-CoV-2 but lack the characteristics of
how MAb362 interacts the ACE2-binding epitope. These neu-
tralizing IgGs, 47D11 and 309, neutralize SARS-CoV-2 with
high potency, but do not block receptor binding to ACE16,38.
Potentially, ACE2 may not be the sole receptor for SARS-CoV-
2, similar to SARS-CoV39, or these antibodies may prevent a
conformational change necessary for viral entry. Further study
of the interaction between MAb362, and other receptor
blocking and neutralizing antibodies against SARS-CoV-2 will
provide insight into the design of vaccine and prophylactic/
therapeutic antibodies against future emerging infections
caused by this viral family.
Methods
S glycoprotein expression and purification. The amino-acid sequence of the
SARS-CoV S glycoprotein (Urbani strain, National Center for Biotechnology
Information [strain no. AAP13441]) and SARS-CoV-2 S glycoprotein sequence
(GeneBank: MN908947) were used to design a codon-optimized version for
mammalian cell expression of the gene encoding the ectodomain of the S glyco-
proteins a.a. 1–1190 (S1–1190) for SARS-CoV and a.a. 1–1255 (S1–1255) for SARS-
CoV-222. The synthetic gene was cloned into pcDNA 3.1 Myc/His in-frame with c-
Myc and 6-histidine epitope tags that enabled detection and purification. Trun-
cated soluble S glycoproteins were generated by polymerase chain reaction (PCR)
amplification of the desired fragments from the vectors encoding S1255 and S1273.
The SARS-CoV-2 RBD constructs carrying point mutation were generated by
following the standard protocol from QuikChange II XL Kit (Agilent). The cloned
genes were sequenced to confirm that no errors had accumulated during the PCR
process. All constructs were transfected into Expi293 cells using ExpiFectamine 293
Transfection Kit (Thermo Fisher).
The plasmid of stabilized trimer of ectodomain of SARS-CoV-2, NIAID
VRC7471, and its expression and purification protocol was kindly provided by
Dr. Kizzmekia S. Corbett, PhD, at Vaccine Research Center of National Institute of
Allergy and Infectious Diseases as part of large-scale production contract awarded to
MassBiologics of UMMS (U24AI126683)22 In this construct, a gene encoding
residues 1−1208 of SARS-CoV-2 S glycoprotein sequence (GenBank: MN908947)
was modified by adding two proline substitutions at residues 986 and 987, a “GSAS”
substitution at residues 682–685, a C-terminal T4 fibritin trimerization motif, an
HRV3C protease cleavage site, a TwinStrepTag and an 8x HisTag. The construct was
cloned into the mammalian expression vector pCDNA 3.1. The construct was then
transfected into Expi293 cells using ExpiFectamine 293 Transfection Kit (Thermo
Fisher). Protein was purified from using StrepTactin resin (IBA) followed by size-
exclusion chromatography using a Superose 6 10/300 column (GE Healthcare).
c
SARS-CoV-2 receptor
(ACE2)
SARS-CoV-2 spike protein RBD
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spike protein
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SARS-CoV-2
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Fig. 3 Predicted MAb362 structural epitope. a Superposition of the space filling molecular model of MAb362 (green) complex on the crystal structure
of the complex of ACE2 (orange) -SARS-CoV-2 RBD (violet) (6VW123) two views are rotated 180°. b The binding interface on SARS-CoV-2 RBD with
ACE2 calculated from the co-crystal structure of the complex. The binding interface shown as darker shade is defined as having vdW contacts great than
−0.5 kcal mol−1. c Positioning of MAb362 on SARS-CoV-2 RBD (violet) relative to the binding of other currently published SARS-CoV-2 RBD-neutralizing
antibodies: CR3022 (PDB: 6W4146; orange); S309 (PDB: 6WPT16; cyan); REGN10933 and REGN10987 (PDB: 6XDG25; magenta and yellow); P2B-2F6
(PDB: 7BWJ26; salmon); CB6 (PDB: 7C0127; wheat) and B38 (PDB: 7BZ528; blue). MAb362 recognized a unique epitope overlapping with the binding
interface of ACE2. d Predicted MAb362 molecular model on the spike trimer in open conformation with one RBD domain exposed 6VYB45.
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All recombinant proteins were purified by immobilized metal chelate affinity
chromatography using nickel-nitrilotriacetic acid (Ni-NTA) agarose beads.
Proteins were eluted from the columns using 250 mmol/L imidazole and then
dialyzed into phosphate-buffered saline (PBS), pH 7.2 and checked for size and
purity by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
The stabilized trimer is also analyzed by high performance liquid chromatography
(HPLC) (Supplementary Fig. 1).
Generation of MAbs. Previously generated frozen hybridomas of anti-SARS-CoV
MAbs9 were recovered and scaled up. Hybridoma supernatants were screened for
reactivity to the SARS-CoV-2 S protein. Positive cell clones were selected for
antibody sequencing. For MAb362, the heavy chain and light chain variable regions
were amplified from hybridoma cells and cloned into an immunoglobulin G1 (IgG)
expression vector. Isotype switching was conducted using primers designed to
amplify the variable heavy chain of the IgG antibody. Products were digested and
ligated into a pcDNA 3.1 vector containing the heavy constant IgA1 chain. The
vector was transformed in NEB5-α-competent cells, and sequences were verified
ahead of transient transfection. IgG and monomeric IgA1 antibodies were trans-
fected in Expi293 cells. Cell supernatants were harvested 5 days post transfection
for antibody purification by protein A sepharose for IgG and Capto L resin for IgA
(GE life Sciences). For dimeric IgA1 (dIgA), the heavy and light chain vectors were
co-transfected with pcDNA-containing DNA for the connecting J chain. For
secretory IgA1 (sIgA) expression, a pcDNA-vector containing gene sequence of
secretory component was added to the transfection reaction in a 1:1 ratio.
Supernatant was run through a column of Capto L resin to capture the light chain
of antibodies (GE life Sciences). Purified antibodies were dialyzed against PBS
before being moved onto size-exclusion chromatography on fast performance
liquid chromatography to separate out the desired dimeric or secretory antibodies
using a HiLoad 26/600 Superdex 200-pg size-exclusion column (GE life Sciences).
The desired fractions were pooled, concentrated, and quality analyzed by SDS-
PAGE and HPLC with representative HPLC profile and gel image shown in
Supplementary Fig. 630.
ELISA. Dilutions of purified MAbs were tested in ELISA for reactivity against
recombinant S protein. In brief, 96-well plates were coated with S proteins followed
by incubation overnight at 4°C. The plates were blocked with 1% BSA with 0.05%
Tween 20 in PBS. Hybridoma supernatant or purified antibody diluted in 1× PBS
plus 0.1% Tween 20 and added to the 96-well plates and incubated for 1 h at room
temperature. Plates were stained with horseradish peroxidase-conjugated anti-
kappa (Company Southern biotech, #2060-05,1:2000 dilution) for 1 h and devel-
oped using 3,3′,5,5′-tetramethylbenzidine. Absorbance at an optical density at
450 nm (OD450) was measured on an Emax precision plate reader (Molecular
Devices) using Softmax Pro v4.3.1 LS.
ELISA-based ACE2-binding assay. In all, 250 ng of ACE2 protein was coated on
ELISA plates overnight at 4 °C. After blocking with 1% BSA in PBS with 0.05% Tween
20 for 1 h at room temperature, threefold of serial dilutions started from 10 µgml−1 of
wild type and point mutations S protein were added into the plates and incubated for
1 h at room temperature. Then plates were stained with mouse-anti-Myc antibody
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Fig. 4 IgA isotype switch enhances MAb362 neutralization of SARS-CoV-2. MAb362 antibody-mediated neutralization of luciferase-encoding
pseudovirions with spike proteins of SARS-CoV a and SARS-CoV-2 b. SARS-CoV and SARS-CoV-2 pseudovirions pre-incubated with serial dilutions of
MAb362 were used to infect 293 cells expressing ACE2 receptor. Pseudoviral transduction was measured by luciferase activities in cell lysates 48 h post
transduction to calculate neutralization (%) relative to non-antibody-treated controls. IC50 values were calculated by nonlinear regression analysis using Prism
version 8.1.1. Isotype switching improved SARS-CoV-2 IC50. Data are plotted as the mean ± s.d. from n= 3 independent experiments a, b. c Dose–response
curve for PRNT with MAb362 at a starting concentration of 50 µgmL−1 titrated 1:2. MAb362 sIgA had a 50% endpoint titer of 9.54 ± 5.88 µgmL−1 calculated
by Spearman–Kärber method, from n= 2 biologically independent experiments. Representative data are plotted with a Probit mid-point analysis curve ± 95%
CI from one experiment with n= 2 technical replicates, using R programming language v3.5.3 and Library ggplot2 v3.3.0 for statistical computing and
graphics47,48. Source data are provided as a Source Data file a–c.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18058-8
6 NATURE COMMUNICATIONS |         (2020) 11:4198 | https://doi.org/10.1038/s41467-020-18058-8 | www.nature.com/naturecommunications
(BD Pharmingen #551101), at 2 µgml−1 for 1 h, followed by horseradish peroxidase-
conjugated goat anti-mouse (Jackson ImmnuoResearch #115-035-062, 1:2000 dilu-
tion) for 1 h and developed using 3,3′,5,5′-tetramethylbenzidine. Absorbance at an
optical density at 450 nm (OD450) was measured on an Emax precision plate reader
(Molecular Devices) using Softmax Pro v4.3.1 LS.
Flow cytometry-based receptor-binding inhibition assay. Vero E6 cells were
harvested with PBS containing 5 mM ethylenediaminetetraacetic acid and ali-
quoted to 1 × 106 cells per reaction. Cells were pelleted then resuspended in PBS
containing 10% FBS. Before mixing with the cells, Myc-tagged SARS-CoV-2 S1–604
was incubated with the MAb at varying concentrations for 1 h at room tempera-
ture, then the S protein was added to the Vero cells to a final concentration of
10 nM. The cells–S protein mixture was incubated for 1 h at room temperature.
After incubation, the cell pellets were washed and then resuspended in PBS with
2% FBS and incubated with 10 µg mL−1 of mouse-anti-Myc antibody (BD Phar-
mingen #551101, 1:100 dilution) for 1 h at 4 °C. Pellets were washed again then
subsequently incubated with a phycoerythrin-conjugated anti-mouse IgG (Jackson
ImmunoResearch, #115-116-071, 1:20 dilution) for 40 min at 4 °C. Cells were
washed twice then subjected to flow cytometric analysis using a MACSquant Flow
Cytometer (Miltenyi Biotec) and analyzed by MACSQuantify Software v2.11 and
FlowJo v10. Binding was expressed as relative to cells incubated with S
proteins only.
Pseudotyped virus neutralization assay. Pseudovirus was generated employing
an HIV backbone that contained a mutation to prevent HIV envelope glycoprotein
expression and a luciferase gene to direct luciferase expression in target cells (pNL4-
3.Luc.R–E–, obtained from Dr. Nathaniel Landau, NIH). SARS-S and SARS2-S spike
protein was provided in trans by co-transfection of 293 T cells with pcDNA-G with
pNL4-3.Luc.R–E–. Supernatant containing virus particles was harvested 48–72 h
post transfection, concentrated using Centricon 70 concentrators, aliquoted, and
stored frozen at −80 degree. Before assessing antibody neutralization, the 293 T cells
were transient transfected with 100 ng pcDNA-ACE2 each well in 96-well plates, and
the cells were used for the pseudovirus infection 24 hs after transfection. A titration
of pseudovirus was performed on 293 T cells transiently transfected with human
ACE2 receptor to determine the volume of virus need to generate 50,000 counts
per second (cps) in the infection assay. The appropriate volume of pseudovirus was
pre-incubated with varying concentrations of MAbs for 1 h at room temperature
before adding to 293 T cells expressing ACE2. 24 h after the infection, the pseudo-
virus was replaced by the fresh complete media, and 24 h after media changing the
infection was quantified by luciferase detection with BrightGlo luciferase assay
(Promega) and read in a Victor3 plate reader (Perkin Elmer) for light production.
Plaque reduction neutralization assay (PRNT). Monoclonal antibody was serially
diluted and incubated with ~70 plaque forming units of wild-type SARS-CoV-2
(2019-nCoV/Victoria/1/2020), for 1 h at 37°C in a humidified box. The virus/anti-
body mixture was then allowed to absorb onto monolayers of Vero E6 [(ECACC
85020206, European Collection of Authenticated Cell Cultures, UK] for 1 h at 37 °C
in a humidified box. Overlay media [MEM (Life Technologies, California, USA)
containing 1.5% carboxymethylcellulose (Sigma), 5% (v/v) fetal calf serum (Life
Technologies) and 25mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buf-
fer (Sigma)] was added and the 24-well plates were incubated in a humidified box at
37 °C for 5 days. Plates were fixed overnight with 20% (w/v) formalin/PBS, washed
with tap water and stained with methyl crystal violet solution (0.2% v/v) (Sigma).
The neutralizing antibody titers were defined as the amount of antibody (µg mL−1)
resulting in a 50% reduction relative to the total number of plaques counted without
antibody, by performing a Spearman–Kärber analysis40 using Microsoft Excel v2016.
An internal positive control for the PRNT assay was run using a sample of human
MERS convalescent serum known to neutralize SARS-CoV-2 (National Institute for
Biological Standards and Control, United Kingdom).
Structural modeling analyses. Three crystal structures, 2GHW the complex of 80
R:SARS-CoV-RBD24, 2AJF the complex of ACE2:SARS-CoV-RBD41, and 6VW1
the complex of ACE2:SARS-CoV-2-RBD23 were used as initial scaffolds in the
determinations of the models of MAb362:SARS-CoV-RBD and MAb362:SARS-
CoV-2-RBD. The amino-acid sequence of MAb362 was aligned to the amino-acid
sequences of 80 R bound SARS-CoV-1 crystal structure (PDB: 2GHW). The point
mutational studies of SARS-CoV-2 RBD were used as restraints to guide the
protein–protein docking of MAb362 against SARS-CoV-2 RBD. The docking was
performed using Glide (Schrödinger software suite v19-4) and Modeller v9.23. The
highest scored docking pose that also best satisfied the mutational analysis was
further optimized through 300 ns molecular dynamic (MD) simulations. The
MD simulations were performed using Desmond (Schrödinger software suite
v19-4)42–44. The final frame of the MD simulations was used as the final structural
model of MAb362-RBD complex.
The structural model of MAb362 binding to the SARS-CoV-2 spike trimer was
based on 6VYB45. All figures were made within PyMOL Molecular Graphics
System v2.3.4 (Schrödinger). The residue van der Waals potential between the
various complexes was extracted from the structures energies using the energy
potential within Desmond.
Mutational scanning to identify MAb362-binding residues. SARS-CoV-2 RBD
residues were individually mutated with a combination of alanine (to introduce a
loss of interaction), tryptophan (to introduce a steric challenge), and lysine
mutations to introduce charge using QuikChange II XL Kit (Agilent) or BioXp
3200 System (SGI-DNA). The genes were cloned into RBD expression vectors and
RBD proteins were purified as described above. Mutant RBDs were confirmed
intact expression on proteins gels, and the same amount of proteins were coated on
the plate for ELISA assays.
Dilutions of purified MAbs were tested in ELISA for reactivity against mutant
RBD proteins. In all, 96-well plates were coated with 100 µl of 5 µg of RBD mutants
followed by incubation overnight at 4°C. The plates were blocked with 1% BSA
with 0.05% Tween 20 in PBS. Purified antibody diluted in 1× PBS plus 0.1% Tween
20 and added to the 96-well plates and incubated for 1 h at room temperature.
Plates were stained with alkaline phosphatase affiniPure goat anti-Human IgG
(Jackson ImmunoResearch #109-055-098, 1:1000 dilution) for 1 h at room
temperature. Alkaline phosphatase affiniPure goat anti-Mouse IgG (Jackson
ImmunoResearch #115-055-003, 1:1000 dilution) was used to detect his tag in a
separate ELISA to verify protein expression and coating. Plates were developed
using p-Nitrophenyl Phosphate (Thermo Fisher Scientific). Absorbance at an
optical density at 405 nm (OD405) was measured on an Emax precision plate
reader (Molecular Devices) using Softmax Pro v4.3.1 LS. ELISAs assay was
performed to determine binding of the MAbs to the mutant proteins compared
with the wild type. Key residues were identified by RBD mutations that reduced
EC50 values relative to the wild-type RBD.
Affinity determination for MAb362. Bio-layer interferometry (BLI) with an Octet
HTX (PALL/ForteBio) was used to determine the affinity of MAb362 IgG and IgA1
to the RBD of SARS-CoV and SARS-CoV-2 S protein. MAbs were added to 96
wells plates at 1000 nM and titrated 1:2 to 62 nM using PBS. RBD of SARS-CoV,
RBD, and ectodomains of SARS-CoV-2 were biotinylated (Thermo Fisher) and
immobilized on Streptavidin Biosensors (ForteBio) for 120 s at 1600 nM con-
centration. After a baseline step, MAb362-antigen binding rate was determined
when the biosensors with immobilized antigen were exposed to MAb362 IgG or
IgA1 at different concentrations for 120 s. Following association, the MAb362-RBD
complex was exposed to PBS and the rate of the MAb362 dissociation from antigen
was measured. Each assay was performed in triplicate. Binding affinities for
MAb362 were calculated using association and dissociation rates with ForteBio
Data analysis software v8.1 (PALL).
Statistical analysis. Statistical calculations were performed using Prism version
8.1.1 (GraphPad Software, La Jolla, CA). EC50 and IC50 values were calculated by
sigmoidal curve fitting using nonlinear regression analysis.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Antibody heavy and light chain sequence can be found on GenBank (MAb362 Heavy
Chain Accession # MT789771, MAb362 Light Chain Accession # MT789772). Database
files used in the study include: PDB 2GHW, the complex of 80 R:SARS-CoV-RBD24;
PDB 2AJF, the complex of ACE2:SARS-CoV-RBD43 and PDB 6VW1, the complex of
ACE2:SARS-CoV-2-RBD. All other data generated are included in figures and tables in
this published article. Source data are provided with this paper. Reprints and permissions
information is available at www.nature.com/reprints.
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